The industry is already celebrating, and every new business pitch mentions the overturning of Schedule III at the federal level. And it’s understandable. The end of 280E alone could mean the difference between a cannabis retailer operating at a loss versus actually posting a profit for the first time. After years of effective tax rates north of 70%, operators are understandably excited about the future. Cannaspire’s Cannabis consultants support operators from application through daily operations.
While a rising tide lifts all ships, this may not be the paradigm shift we all seem to think it is. Rather, it’s the start of a long series of federal shakeups, missteps, and false starts, which only seem progressive in light of decades of prohibition and federal inaction. Many operators bring in cannabis compliance consulting to stay ahead of these requirements.
In over a decade of cannabis regulatory compliance, having helped secure more than 200 business licenses across medical and adult-use markets nationwide, I’ve watched this industry celebrate prematurely before. And I’ve seen what happens to operators who don’t recognize the inherent risk this regulatory uncertainty poses for the industry at large, with the national intoxicating hemp ban being the most visible example of the sweeping effects these federal changes create.
Rescheduling is not legalization. And for a startling number of cannabis businesses, it may be the beginning of the hardest compliance chapter they’ve ever faced.
What’s worse? The federal agencies responsible for making any of this work — the DEA, FDA, and USDA — are tripping over each other. Deadlines are being missed, and hearings are stalled. Contradictory guidance is being issued simultaneously. And operators are caught in the middle of what may be the most complex regulatory pileup this industry has ever seen.
Yes, the elimination of IRC Section 280E will let you deduct rent, payroll, marketing, and normal operating expenses for the first time. That’s transformative. The Congressional Research Service has detailed how 280E has denied cannabis businesses deductions and credits for decades, resulting in effective tax rates that can exceed 70–80%. Only 27.3% of U.S. cannabis operators were profitable in 2024. Compare that to roughly 65% of all small businesses in the country.
But here’s what nobody on your LinkedIn feed is telling you: the moment you start filing like a normal business, you’d better be operating like one.
280E, for all its cruelty, created an odd kind of cover. When the IRS knows you can’t deduct anything, they’re not exactly combing through your expense categories with a fine-tooth comb. That changes overnight under Schedule III. Now every deduction you claim needs to be documented, defensible, and compliant, not just with state cannabis regulations, but with the same federal standards that apply to every other Schedule III business in America.
Your entity structure suddenly matters in ways it never did before. The difference between an LLC, S-Corp, and C-Corp becomes materially significant under normalized tax treatment. Employee Stock Ownership Plans become economically viable. M&A opportunities emerge as companies seek to shed historical 280E liabilities. These are conversations your compliance team and your accountants should be having right now, rather than after the final rule drops.
If your books are messy, your SOPs are collecting dust, and your Metrc reconciliations are “close enough”, you are not prepared for this new heightened level of scrutiny from banks and federal agencies.
Here’s a detail that gets lost in the hype, the executive order President Trump signed on December 18, 2025 does not reschedule marijuana. It directs the Attorney General to complete the rulemaking process “in the most expeditious manner.” That’s an important distinction, because the process is nowhere close to finished.
The DEA’s proposed rule to move marijuana from Schedule I to Schedule III was published in May 2024. It received nearly 43,000 public comments. An administrative hearing was scheduled to begin January 21, 2025, but the presiding Administrative Law Judge postponed it after an interlocutory appeal was filed, citing allegations of DEA bias and improper ex parte communications with anti-rescheduling parties.
As of April 2026, that appeal remains pending. No briefing schedule has been set. The DEA confirmed on April 10 that it has not taken additional steps relating to the proposed rescheduling. The process is functionally frozen.
There are two possible pathways forward. The Attorney General could use an expedited “treaty exception” under Section 811(d)(1) of the Controlled Substances Act to bypass the stalled hearing entirely, but that would almost certainly trigger immediate litigation. Alternatively, the DOJ could pursue standard rulemaking, which means restarting the hearing, completing post-hearing briefings, receiving the Administrative Law Judge’s recommendation, and then publishing a final rule. Legal analysts estimate that even in an optimistic scenario, a final rule taking effect in early-to-mid 2027 is the fastest realistic timeline. Late 2027 or 2028 is a more conservative planning baseline.
Anti-rescheduling groups have already retained former Trump Attorney General Bill Barr to sue to reverse rescheduling if a final rule is issued. So the timeline stall due to litigation still is uncertain, but what isn’t uncertain is that litigation is coming.
What does this mean for operators? Well, you’re planning business operations around a policy that may not materialize for another 12–24 months, and when it does arrive, it will land in a courtroom before it lands in your accounting software. Plan for both scenarios: model your P&L with 280E intact and without. Don’t bet the business on timing you can’t control.
Schedule III substances fall entirely under FDA regulatory authority. The cannabis industry has operated for years in a world where the FDA was essentially a bystander. That era is ending.
What does FDA oversight look like for cannabis? Nobody knows for certain yet, and that ambiguity is itself a compliance risk. But we can look at how every other Schedule III substance is regulated: manufacturing standards, labeling requirements, quality control protocols, adverse event reporting, and current Good Manufacturing Practices (cGMP).
Here’s the problem: the agency that’s about to become your new regulator can’t even meet the deadlines Congress has already given it.
As part of the November 2025 appropriations legislation, Congress mandated that FDA publish, within 90 days, a list of all cannabinoids naturally produced by the cannabis plant, a list of all THC-class cannabinoids, a list of cannabinoids with “similar effects” to THC, and additional guidance defining the term “container” for hemp product THC limits. The deadline was February 10, 2026.
The FDA completely missed it, and as of mid-April 2026, none of those lists exist.
This isn’t a minor bureaucratic speedbump. Those lists are foundational definitions underlying the entire hemp regulatory framework. Without them, businesses cannot determine which products will be compliant with the new rules taking effect in November. The law grants Health and Human Services unlimited authority to designate additional cannabinoids as THC-like and sweep them into the 0.4mg combined cap, but nobody knows which compounds that includes because the agency tasked with defining them hasn’t done its job.
Jonathan Miller, general counsel of the U.S. Hemp Roundtable, put it bluntly: the FDA has a pattern of being slow to meet, or outright ignoring, congressional deadlines when it comes to hemp.
Meanwhile, in March 2026, the FDA submitted a CBD Products Compliance and Enforcement Policy to the Office of Management and Budget for review, signaling the agency is working on enforcement before it’s even clarified what’s legal. And in an almost comical contradiction, the Centers for Medicare and Medicaid Services is launching a Medicare pilot program in April 2026 covering hemp-derived CBD products for eligible patients with a THC limit of 3 milligrams per serving. That’s more than seven times the 0.4mg per container limit in the hemp ban. Two federal agencies, two wildly different standards, zero coordination.
I’ve spent years helping clients build SOPs, conduct facility audits, and implement quality systems aligned with state-specific regulations. The operators who invested in that infrastructure are about to have a massive competitive advantage. The ones who treated compliance like fire-fighting rather than fire prevention? They’re about to find out what real audits look like, that is, if anyone can even tell them what the rules are.
One of the biggest myths floating around is that Schedule III will solve cannabis banking. It won’t. Not fully, not quickly. Between the Clarity Act and crypto’s new role in the global banking system, there’s a lot going on at the federal level, and fixing the cannabis industry’s woes is too low stakes.
Schedule III may increase comfort for some financial institutions, but the core Anti-Money Laundering and Bank Secrecy Act frameworks don’t change just because the scheduling does. FinCEN’s marijuana banking guidance is now over a decade old, and despite repeated calls for revision, the agency has shown no indication it intends to update it. As one banking compliance expert put it: nothing meaningfully changes for banks until FinCEN acts, and there’s little indication that it will.
Without legislative action like the SAFER Banking Act, cannabis businesses will still face limited access to traditional banking, capital markets, payment processors, and federal trademark registration. The SAFER Banking Act was reintroduced in early 2026 with 14 bipartisan Senate cosponsors, and a coalition of 32 state attorneys general sent a letter to Congress in July 2025 urging its passage, arguing it would bring billions into the banking sector and enable law enforcement to more effectively monitor cannabis transactions. But the bill’s road through Congress remains uncertain: the Senate Banking Committee is now chaired by Senator Tim Scott, who opposes the reform, and Senate Majority Leader Thune has expressed similar opposition.
What will change under Schedule III is that banks who do work with you will expect more from you. More documentation. More transparent financials. More compliance infrastructure. If you’ve been operating on cash and handshake accounting, the window to professionalize is closing fast.
While everyone’s focused on Schedule III, there’s a parallel crisis that could reshape the entire cannabinoid marketplace, and it has a hard deadline that, unlike rescheduling, isn’t stuck in bureaucratic limbo.
On November 12, 2025, Congress passed a provision, Section 781 of the FY2026 agriculture appropriations bill, that fundamentally rewrites the federal definition of hemp. It shifts from a delta-9 THC standard to total THC concentration, caps finished hemp products at 0.4 milligrams of total THC per container and bans all synthetically derived cannabinoids. The effective date is November 12, 2026.
This was not debated in a standalone hearing. It was inserted by Rep. Andy Harris (R-MD) into a must-pass spending bill to reopen the government after a 42-day shutdown. Senator Rand Paul tried to strip the language and lost 76–24.
The U.S. Hemp Roundtable estimates this will eliminate approximately 95% of existing hemp-derived cannabinoid products, not just intoxicating products, but a broad range of non-intoxicating wellness products, including most full-spectrum CBD formulations. The corresponding economic impact: over 300,000 jobs and $1.5 billion in state tax revenue at risk. Farmers who transitioned from tobacco to hemp cultivation, many of whom had already committed capital for the 2026 planting season, face the prospect of harvesting a crop that could be classified as a Schedule I controlled substance.
There are currently four legislative tracks attempting to address the hemp ban, but none have passed to date:
The American Hemp Protection Act (H.R. 6209), introduced by Rep. Nancy Mace (R-SC) with bipartisan cosponsors including Reps. Massie, Lofgren, and Baird, would repeal Section 781 entirely, but offers no regulatory framework to replace it.
The Hemp Planting Predictability Act (H.R. 7024), introduced by a bipartisan group including Senators Klobuchar, Paul, and Merkley, would delay the effective date by two years to November 2028, buying the industry time to negotiate.
The Cannabinoid Safety and Regulation Act from Senators Wyden and Merkley would replace the ban with a federal regulatory framework: 5mg THC per serving, 50mg per container, age-21 minimum, mandatory testing, and standardized packaging.
And the 2026 Farm Bill advanced through the House Agriculture Committee in March on a 34-17 vote, but without any amendments to delay or repeal the hemp ban. Chairman Thompson ruled that regulating finished hemp products falls under the Energy and Commerce Committee, not Agriculture.
The lobbying effort is massive. Hemp industry groups, alcohol companies, including the Wine & Spirits Wholesalers of America, farmers’ coalitions, and even some cannabis operators have aligned. Rep. James Comer (R-KY) held a press conference with hemp farmers warning the ban would destroy opportunities Congress itself created in the 2018 Farm Bill. The Kentucky delegation, a state where hemp replaced tobacco as a lifeline crop, has been particularly vocal.
But the 76–24 Senate vote that failed to strip the language tells you the political math. A full repeal is unlikely. A delay or a regulate-don’t-ban framework is more plausible, but far from guaranteed before the November deadline hits.
If you’re operating in the hemp-derived cannabinoid space, your compliance team should be scenario-planning right now. Not next quarter. Right now.
I hear it constantly: “Once we’re Schedule III, we can ship across state lines.” No. You cannot. Rescheduling alone does not authorize state-licensed operators to move product interstate. The Congressional Research Service has been explicit: moving marijuana to Schedule III would not bring the state-legal cannabis industry into compliance with federal controlled substances law. Multi-state operators need to continue planning for state-by-state compliance, separate supply chains, and localized operations.
This is one of the most dangerous misconceptions in the industry right now, because operators are making capital allocation decisions based on it. They’re signing leases, hiring teams, and building out infrastructure under the assumption that interstate commerce is around the corner. It isn’t.
Step back for a moment and look at the full picture of what’s happening at the federal level:
The DEA has a rescheduling process that’s been frozen since January 2025 due to an interlocutory appeal over the agency’s own alleged misconduct. Despite a presidential executive order directing them to move expeditiously, their April 2026 status report says the matter “remains pending” with no briefing schedule set. The agency nominated to lead it, Terrance Cole, told senators that examining the rescheduling proposal would be “one of my first priorities,” but his confirmation isn’t finalized. The agency that’s supposed to reclassify cannabis can’t even get past its own internal procedural mess.
The FDA missed its congressionally mandated February 2026 deadline to publish the cannabinoid lists foundational to the hemp regulatory framework. It’s simultaneously developing enforcement policy for CBD products and reviewing a Medicare pilot program that uses THC limits seven times higher than the hemp ban allows. The agency that’s about to oversee Schedule III cannabis products is already demonstrating it can’t keep pace with the regulatory demands Congress has placed on it.
The USDA is caught in the middle, the Farm Bill reauthorization includes hemp provisions for industrial producers, but the committee chair has explicitly refused to address the consumable product ban, calling it someone else’s jurisdiction.
And FinCEN, the agency whose guidance determines whether banks will serve cannabis businesses, hasn’t updated its marijuana banking framework since 2014.
This is not a coordinated federal response. These are four agencies operating on different timelines, with different priorities, under different mandates, producing contradictory guidance, while an industry supporting 425,000 jobs and generating nearly $47 billion in projected 2026 revenue tries to figure out what’s legal.
I don’t write this to rain on the parade. I write this because I’ve watched too many operators lose their licenses, and their livelihoods, because they weren’t prepared for the compliance environment they were operating in.
Here’s what I’m telling every client at Cannaspire right now:
Audit your SOPs immediately. Not next quarter, not when the final rule drops. Now. If your standard operating procedures haven’t been updated in the last 12 months, they’re already behind. State regulations have shifted, best practices have evolved, and federal expectations are about to get more granular than anything this industry has seen.
Stress-test your financials under both scenarios. Model your P&L with 280E intact and without. Evaluate your entity structure, LLC, S-Corp, C-Corp, because those choices become materially significant under normalized tax treatment. Don’t restructure prematurely but have the plan ready.
Get your seed-to-sale house in order. Daily reconciliation between your Metrc system, your ERP, and your bank feeds isn’t optional anymore. It’s the bare minimum. The operators who are running three-way checks daily are the ones who’ll survive the next wave of scrutiny and transparency requirements.
Invest in quality systems now. cGMP, GAP, HACCP, ISO 22000, these aren’t buzzwords for big corporations. They’re the compliance infrastructure that separates operators who thrive under Schedule III from those who get buried by it. When FDA oversight arrives, the question won’t be whether you’re compliant, it’ll be whether you can prove it.
If you touch hemp-derived cannabinoids, scenario-plan for November. Map every SKU against the new definition. Audit your supply chain. Review every contract for hemp-definition dependencies. The November 12, 2026 deadline will arrive whether the FDA publishes its guidance or not, and operators who wait for clarity may find it arrives after the deadline, not before.
Build relationships with compliance professionals who know this space. Not general business consultants. Not your accountant’s nephew who “knows about weed.” People who have lived in the regulatory weeds across multiple state markets, who understand the difference between what the law says and how regulators actually enforce it.
The cannabis industry is about to undergo its most significant structural transformation since state-level legalization began. Schedule III rescheduling, whenever it actually happens, the hemp definition overhaul, evolving state regulations, a pending Farm Bill, FDA enforcement policy under OMB review, a SAFER Banking Act with uncertain prospects, and a DEA that can’t get out of its own way. All converging at once.
This is not a moment to coast. This is a moment to build.
The businesses that invested in compliance infrastructure when it was “optional” are about to see that investment pay off in ways they never imagined. And the businesses that treated compliance as an afterthought are about to learn the most expensive lesson in cannabis: your license is only as strong as the systems that support it.
I’ve dedicated my career to helping cannabis businesses not just get licensed but stay licensed. The operators who take this moment seriously, who treat Schedule III not as a victory lap but as the starting gun for a new era of accountability are the ones who will still be standing five years from now.
The rest will be case studies in what happens when you confuse a policy shift with a free pass.
Warren Harasz, PhD is the Chief Compliance Officer and Managing Partner at Cannaspire, a leading international cannabis consulting firm. With over a decade of experience in cannabis regulatory compliance, Warren has contributed to securing more than 200 business licenses across medical and adult-use markets nationwide. He specializes in business license applications, SOPs, facility audits, fractional compliance, and helping cannabis businesses build the operational frameworks they need to stay compliant for the long haul. Reach Cannaspire at cannaspire.com.
Minnesota cannabis buildout guide: the 18-month clock, zoning and local registration, security rules, Metrc onboarding, and OCM inspection readiness.
What it takes to fund a Virginia cannabis business before the February 2027 application window — capital stack, investor structures, CCA disclosure rules, and 280E math.
How hemp operators move into licensed cannabis before the federal 0.4 mg THC cap takes effect: the four realistic paths, what transfers, and what to do in the next 90 days.
